Bicara Therapeutics Announces Inducement Grant

Biotech company grants stock options to new employees under Nasdaq rules

Apr. 3, 2026 at 2:45pm

Got story updates? Submit your updates here. ›

A minimalist studio still life photograph featuring a stack of medical research papers, a pen, and a pair of reading glasses arranged elegantly on a clean, monochromatic background, conceptually representing the strategic decisions and financial considerations in the biotech industry.Bicara Therapeutics' latest inducement grant aims to bolster its team as the biotech company advances its clinical pipeline.Boston Today

Bicara Therapeutics, a clinical-stage biopharmaceutical company, has announced an inducement grant of stock options to new employees. The grant was made under Nasdaq Listing Rule 5635(c)(4), which allows companies to issue securities as inducements to new hires without shareholder approval.

Why it matters

Inducement grants are a common practice in the biotech industry to attract and retain top talent. By offering stock options, companies can incentivize new employees to work towards the company's long-term success. This announcement demonstrates Bicara's efforts to build out its team as it advances its clinical pipeline.

The details

The inducement grant includes the issuance of stock options to purchase an aggregate of 75,000 shares of Bicara's common stock. The options have an exercise price of $25.50 per share, which was the closing price of Bicara's common stock on the grant date. The options will vest over a four-year period, with 25% vesting on the one-year anniversary of the employee's start date and the remaining 75% vesting in equal monthly installments over the following 36 months.

  • The inducement grant was announced on April 3, 2026.

The players

Bicara Therapeutics Inc.

A clinical-stage biopharmaceutical company focused on developing innovative cancer therapies.

Got photos? Submit your photos here. ›

The takeaway

Inducement grants are a common practice in the biotech industry to attract and retain top talent. Bicara's announcement demonstrates its efforts to build out its team as it advances its clinical pipeline, which is a positive sign for the company's future growth and development.